I think this points to where the Wafertab machine is going.
"Richard Trevillion, CEO of BioProgress, said: 'I am delighted to welcome the
management and staff of Dexo into the BioProgress group. Our technology lends
itself to rapid brand differentiation and improvement, particularly in areas of
patient compliance and product life cycle extension."
Patient complience points to DITM strips in my mind. Also product life cycle extension may mean extension of patents.
I think that there is a lot of reserve and understatement in this RNS and the full significance of it is still to be fully understood by the market.
Remember the registration of Dexo Biogenerics? No mention of biogenerics in this RNS but by the registration of that name, I am sure biogenerics will feature within the company.
More machines needed for this development. HH are going to be busy.
Bioprogress stock quotes
Bioprogress stock charts
Follow this thread
